Results 161 to 170 of about 996,617 (405)

Steroid Hormones and Endocrine Disruptors: Recent Advances in Receptor–Mediated Actions [PDF]

, 2017
It has been accepted that receptor-mediated action of steroid hormones depends on both the receptor and the hormonal level. The mechanism of transcription by steroid receptors is mediated by cofactors, which function as co-activators or co ...
Indarto, Dono, Izawa, Masao
core  

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Journal of the American Medical Association (JAMA), 2002
J. Rossouw, G. Anderson, Ross L. Prentice, Andrea Z LaCroix, C. Kooperberg, M. L. Stefanick, R. Jackson, Shirley A. A. Beresford, Barbara V. Howard, Karen C. Johnson, J. Kotchen, Judith Ockene   +11 more
semanticscholar   +1 more source

Stimuli‐Responsive CuFeTe2 Nanosheets for Amplified Cuproptosis/Ferroptosis in Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
Dual‐stimuli‐responsive CuFeTe2 nanosheets (CFT) induce cuproptosis/ferroptosis via TME‐responsive Fe2⁺/Cu2⁺ release and NIR‐II photothermal effects, amplifying ROS and depleting HSP70/ATP to trigger ICD and immune activation, while ensuring biocompatible renal clearance for TNBC therapy.
Molin Liu, Jian Zheng, Mengqi Yu, Qirui Wang, Yi Yuan, Nannan Shao, Xiaoliang Yang, Tianxi Shen, Li Wang, Aiyun Li, Rui Liu, Jimin Cao, Xi Liu, Fangfang Cao, Yanlin Feng   +14 more
wiley   +1 more source

Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang, Sheyu Zhang, Lu Guo, Yichun Pan, Juan Huang, Yishuai Ji, Jiaqi Tao, Yong Wei, Xiaojia Wang, Qin Wu   +9 more
wiley   +1 more source

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Journal of the American Medical Association (JAMA), 1998
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, Betty S. Riggs, E. Vittinghoff   +6 more
semanticscholar   +1 more source

Single‐Cell Dissection of the Biological Function and Molecular Features Underlying the Micropeptide LSMEM1 in Kidney

Advanced Science, EarlyView.
LSMEM1, an evolutionarily conserved micropeptide with extreme hydrophobicity (aliphatic index═113) and dynamic amphiphilicity (GRAVY═0.017), features a strong α‐helical transmembrane anchor (residues 64‐86). Single‐cell analysis reveals its critical role in renal lipid homeostasis.
Peimin Liu, Hong Zhang, Shanzhi Yang, Jiaoqing Li, Danfeng Wu, Haosen Xu, Huan Jiang, Yi Jing, Guoxiang Jin, Ruobing Liu, Ning Fan, Xiaoyan Bai   +11 more
wiley   +1 more source

Hepatic KLF9 Deficiency Inhibits Dehydroepiandrosterone (DHEA)‐Induced Polycystic Ovary Syndrome via Liver‐Ovary Axis

Advanced Science, EarlyView.
The study shows that liver is a previously unrecognized extraovarian organ that plays a key role about androgen homeostasis in the development of DHEA‐induced PCOS. DHEA is the most common precursor of active androgen, such as DHT, and KLF9 is required for the conversion of DHEA to DHT and hepatic KLF9 might be a potential therapeutic target for PCOS ...
Jianli Song, Zhaoqing Guan, Guiyi Ji, Jing Wang, Xiurui Yan, Yujie Zhang, Yinliang Zhang, Chunfang Ha, Rong Hu, Yongsheng Chang, Yaolin Zhang, Heng Fan   +11 more
wiley   +1 more source

Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β.

Endocrinology, 1998
G. Kuiper, J. Lemmen, B. Carlsson, J. Corton, S. Safe, P. T. van der Saag, B. van der Burg, J. Gustafsson   +7 more
semanticscholar   +1 more source

Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6

Advanced Science, EarlyView.
Metformin has a biological activity against breast cancer. However, it is largely unknown about its precise therapeutic targets. Here, histone arginine methyltransferase PRMT6 is identified as a new anti‐cancer target for metformin. Metformin directly binds PRMT6 and inhibits its ability to catalyze histone H3R2 asymmetric dimethylation (H3R2me2a ...
Yinsheng Wu, Xinlin Xu, Yue Tong, Min Wang, Feng Ge, Min Wu, Yunlong Wang, Gang Chen, Xilan Yu, Shanshan Li   +9 more
wiley   +1 more source

Sexual differentiation of estrogen receptor alpha subpopulations in the ventromedial nucleus of the hypothalamus [PDF]

, 2023
Laura R. Cortes, H. Sturgeon, Nancy G. Forger   +2 more
openalex   +1 more source